Key result
High serum miR-222-3p linked to ~74% lower odds of pCR in HER2-positive breast cancer.
Why the study?
It was unknown whether serum miR-222-3p expression could contribute to early prediction of therapeutic response, clinical outcomes, and adverse events in HER2-positive breast cancer patients receiving neoadjuvant therapy.
Does serum miR-222-3p expression predict therapeutic efficacy and trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients receiving neoadjuvant therapy?
Cohort (n=65)
No
Does serum miR-222-3p expression predict therapeutic efficacy and trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients receiving neoadjuvant therapy?
Serum miR-222-3p may serve as a dual-purpose biomarker to predict both therapeutic response and risk of trastuzumab-induced cardiotoxicity in HER2-positive breast cancer.
May support miR-222-3p for pCR prediction in HER2+ breast cancer; hypothesis-generating and requires prospective validation before use.
Background: We aimed to explore whether the expression of serum miR-222-3p might contribute to early prediction of therapeutic response, clinical outcomes and adverse events for HER2-positive breast cancer patients receiving neoadjuvant therapy (NAT). Methods: A total of 65 HER2-positive breast cancer patients receiving NAT were analyzed. The concentration of serum miR-222-3p was detected by quantitative real-time PCR. Logistic regression analysis was used to identify the association of serum miR-222-3p with pathological complete response (pCR). The relationship of serum miR-222-3p with disease-free survival (DFS) and overall survival (OS) was examined via log-rank test and Cox proportional hazards analysis. The ordered logistic regression was applied to evaluate the association between serum miR-222-3p and adverse events. Results: The miR-222-3p low group was more likely to achieve pCR [odds ratio (OR) = 0.258, P = 0.043]. The interaction between miR-222-3p and presenting Ki67 level was also detected for pCR (OR=49.230, Pinteraction = 0.025). The miR-222-3p low group was correlated with superior DFS (P = 0.029) and OS (P = 0.0037). The expression of serum miR-222-3p was the independent protective factor for trastuzumab-induced cardiotoxicity (P < 0.05) and anemia (P = 0.013). Conclusions: Serum miR-222-3p is the potential factor to predict pCR, survival benefit and trastuzumab-induced cardiotoxicity for HER2-positive breast cancer patients receiving NAT.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2020) conducted a cohort in HER2-positive breast cancer (n=65). Low serum miR-222-3p vs. High serum miR-222-3p was evaluated on Pathological complete response (pCR) (OR 0.258, 95% CI 0.070-0.958, p=0.043). Low serum miR-222-3p levels were significantly associated with a higher likelihood of achieving pathological complete response (OR 0.258 for high vs. low) in HER2-positive breast cancer patients receiving neoadjuvant therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: